Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
Terminated
National Cancer Institute (NCI)
Phase 1/Phase 2
2006-10-01
This phase I/II trial studies the side effects and best dose of calcitriol when given in
combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in
treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more
like normal cells and grow and spread more slowly. Ketoconazole and therapeutic
hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the
drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a
better treatment for prostate cancer.
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
Terminated
Roswell Park Cancer Institute
Phase 1/Phase 2
2006-10-01
This phase I/II trial studies the side effects and best dose of calcitriol when given in
combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in
treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more
like normal cells and grow and spread more slowly. Ketoconazole and therapeutic
hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the
drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a
better treatment for prostate cancer.
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Active, not recruiting
National Cancer Institute (NCI)
Phase 3
2008-01-14
This phase III trial studies combination chemotherapy with or without lestaurtinib with to
see how well they work in treating younger patients with newly diagnosed acute lymphoblastic
leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. It is not yet known whether combination chemotherapy is more
effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
